PCM
SLNO

Peregrine Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Peregrine Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-119,564
Closed -$5.54M – 317
2025
Q4 		$5.54M Buy
119,564
+26,559
+29% +$1.46M 0.17% 174
2025
Q3 		$6.29M Buy
+93,005
New +$6.9M 0.19% 155

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.19B AUM 14.29% 1-Year Est. Return

Peregrine Capital Management's SLNO Position: Q1 2026 in Review

Peregrine Capital Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 119,564 shares — an estimated $5.54M sold.

Peregrine Capital Management first reported a position in SLNO in Q3 2025 and held it in 2 quarters. The position peaked at $6.29M in Q3 2025. 227 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Peregrine Capital Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Peregrine Capital Management sold 119,564 Soleno Therapeutics shares in Q1 2026, an estimated $5.54M.
  • Peregrine Capital Management first reported a position in Soleno Therapeutics in Q3 2025 and held it in 2 quarters.
  • Peregrine Capital Management's Soleno Therapeutics position peaked at $6.29M in Q3 2025.
  • 227 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Peregrine Capital Management's 13F filing for Q1 2026, filed 23 Apr 2026.